Multicentric Evaluation of the Bio-Evolution Toxoplasma gondii Assay for the Detection of Toxoplasma DNA in Immunocompromised Patients

J Clin Microbiol. 2020 Jan 28;58(2):e01231-19. doi: 10.1128/JCM.01231-19. Print 2020 Jan 28.

Abstract

PCR-based methods are a key tool for the diagnosis of toxoplasmosis in immunocompromised patients. Laboratory-developed protocols lack standardization. This study aimed to assess the performances of a commercial kit for the detection of Toxoplasma DNA in different specimens drawn from immunocompromised patients. This multicentric retrospective study included 227 DNA specimens (157 blood specimens, 22 bronchoalveolar fluid [BALF] specimens, 39 cerebrospinal fluid [CSF] specimens, and 9 miscellaneous specimens) collected between 2010 and 2015 from 126 immunocompromised patients. The specimens were selected based on previous laboratory-developed quantitative PCR (qPCR) analyses targeting either the rep529 element or the B1 gene, and the results were classified as positive, negative, and "negative of interest," where the latter was defined as representing either the last specimen with a negative result before a positive one or the first with a negative result following a positive result(s). All specimens were secondary tested using the Bio-Evolution Toxoplasma DNA assay targeting the T. gondii rep529 element. We found a 95.6% concordance rate for qualitative results obtained with laboratory-developed qPCR techniques and the commercial kit. The rate reached 99.3% in comparisons of rep529-based laboratory-developed PCR methods and the commercial kit. The quantifications obtained with the commercial kit and the rep529 laboratory-developed PCRs were in very good agreement. Sensitivity and specificity of the commercial kit were calculated at 98.8% and 100%, respectively. The Bio-Evolution Toxoplasma DNA assay appears to be a valuable method for the detection of Toxoplasma DNA in blood, BALF, and CSF specimens from immunocompromised patients.

Keywords: immunocompromised patients; quantitative PCR; toxoplasmosis.

Publication types

  • Multicenter Study

MeSH terms

  • DNA, Protozoan / genetics*
  • Humans
  • Immunocompromised Host*
  • Molecular Diagnostic Techniques / methods
  • Molecular Diagnostic Techniques / standards*
  • Reagent Kits, Diagnostic / standards*
  • Real-Time Polymerase Chain Reaction / standards
  • Retrospective Studies
  • Sensitivity and Specificity
  • Toxoplasma / genetics*
  • Toxoplasmosis / blood
  • Toxoplasmosis / cerebrospinal fluid
  • Toxoplasmosis / diagnosis*

Substances

  • DNA, Protozoan
  • Reagent Kits, Diagnostic